Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2019-03-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
关于变更会计政策的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about changes in accounting policies, including details on the reasons for changes, the new policies adopted, and the impact on financial statements. It references regulatory accounting standards issued by the Ministry of Finance and includes approvals from the board, independent directors, and supervisory board. The document is relatively short (3754 characters) and does not contain actual financial statements or detailed financial data. It is a formal announcement of accounting policy changes rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2019-03-28 Chinese
2018年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for 华兰生物工程股份有限公司 covering the fiscal year from January 1, 2018 to December 31, 2018. It includes detailed auditor opinions, key audit matters, and extensive financial statements such as consolidated balance sheets, income statements, cash flow statements, and equity changes. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content focuses on the audit process, auditor responsibilities, and detailed financial data, which aligns with the definition of an Audit Report / Information (AR). It is not an Annual Report (10-K) because it lacks broader company activity and management discussion sections, nor is it a Regulatory Filing or Report Publication Announcement since it contains the full audit report and financial statements. Therefore, the document is best classified as an Audit Report / Information (AR). FY 2018
2019-03-28 Chinese
独立董事提名人声明（三）
Board/Management Information Classification · 95% confidence The document is a public statement from the board of directors nominating an independent director candidate for the company's board. It contains detailed declarations about the nominee's qualifications, compliance with laws and regulations, and independence criteria. There are no financial statements, earnings data, or report attachments. The content is related to board/management information, specifically about a nomination for a board position. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 3375 characters, which is relatively short but contains substantive content about management nomination rather than a mere announcement or certification.
2019-03-28 Chinese
2018年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2018 by 华兰生物工程股份有限公司. It discusses the company's internal control evaluation, including financial and non-financial internal control effectiveness, organizational structure, governance, risk management, and compliance with internal control standards. It does not contain full financial statements or quarterly/annual financial results but focuses on internal control assessment and related disclosures. This type of document is a standalone audit-related report focusing on internal control evaluation rather than a full annual report or interim report. Therefore, it fits best under the category of Audit Report / Information (AR). The document length (6644 characters) and detailed content support this classification with high confidence. FY 2018
2019-03-28 Chinese
独立董事2018年度述职报告（苏志国）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2018 Annual Work Report" for a company, detailing the independent director's activities, opinions on various company matters including internal control, audit firm appointment, investment, profit distribution, and stock incentive plans during the year 2018. It includes detailed independent opinions on financial and governance matters, attendance at board meetings, and compliance with regulatory requirements. The document is a detailed report by an independent director on their duties and observations for the year, which is a form of management or board-related reporting rather than a full annual report or audit report. It is not a transcript, earnings release, or a simple announcement. The content focuses on board/management information and independent director opinions, which aligns best with the category Board/Management Information (MANG).
2019-03-28 Chinese
独立董事候选人声明（田莉军）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of a company, affirming compliance with various legal and regulatory requirements for serving as an independent director. It includes statements about qualifications, independence, and adherence to relevant laws and regulations. There is no financial data, no discussion of financial results, no mention of meetings or voting results, no audit information, no capital or financing updates, and no other report types. This document is a formal declaration related to board/management information, specifically concerning the appointment or status of a board member. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters, but it is not an announcement of a report publication; it is the declaration itself, so it is not RPA or RNS.
2019-03-28 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.